TCM
ABBV icon

TD Capital Management’s AbbVie ABBV Stock Holding History

TD Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169K Sell
778
-44
-5% -$9.76K 0.02% 147
2025
Q4 		$188K Buy
822
+137
+20% +$31.2K 0.02% 129
2025
Q3 		$159K Buy
685
+5
+0.7% +$1.02K 0.01% 138
2025
Q2 		$126K Buy
680
+552
+431% +$103K 0.01% 146
2025
Q1 		$26.8K Buy
128
+58
+83% +$11.3K ﹤0.01% 231
2024
Q4 		$12.5K Buy
70
+16
+30% +$2.94K ﹤0.01% 272
2024
Q3 		$10.8K Hold
54
– – ﹤0.01% 284
2024
Q2 		$9.27K Hold
54
– – ﹤0.01% 283
2024
Q1 		$9.75K Buy
54
+1
+2% +$172 ﹤0.01% 286
2023
Q4 		$8.22K Sell
53
-340
-87% -$49.6K ﹤0.01% 296
2023
Q3 		$58.5K Buy
393
+4
+1% +$587 0.01% 161
2023
Q2 		$52.4K Buy
389
+3
+0.8% +$440 0.01% 171
2023
Q1 		$61.4K Sell
386
-21
-5% -$3.21K 0.01% 161
2022
Q4 		$65.7K Buy
407
+29
+8% +$4.45K 0.01% 144
2022
Q3 		$51K Buy
+378
New +$54.2K 0.01% 159
2022
Q1 		– Sell
-439
Closed -$59K – 95
2021
Q4 		$59K Sell
439
-106
-19% -$12.5K 0.01% 152
2021
Q3 		$59K Buy
545
+4
+0.7% +$457 0.01% 145
2021
Q2 		$61K Buy
541
+5
+0.9% +$563 0.01% 135
2021
Q1 		$58K Buy
536
+126
+31% +$13.5K 0.01% 130
2020
Q4 		$44K Buy
410
+5
+1% +$480 0.01% 135
2020
Q3 		$35K Buy
+405
New +$38.1K 0.01% 133
2019
Q3 		– Sell
-455
Closed -$33K – 259
2019
Q2 		$33K Buy
+455
New +$35.8K 0.01% 123
2017
Q4 		– Sell
-112
Closed -$10K – 183
2017
Q3 		$10K Buy
+112
New +$8.53K ﹤0.01% 134

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TD Capital Management's ABBV Position: Q1 2026 in Review

TD Capital Management reduced its AbbVie (ABBV) stake by 5.4% in Q1 2026, selling an estimated $9.76K and leaving 778 shares worth $169K. The position accounts for 0.02% of the portfolio, ranked #147.

TD Capital Management first reported a position in ABBV in Q3 2017 and has held it in 23 quarters since. The position peaked at $188K in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • TD Capital Management held 778 shares of AbbVie worth $169K as of Q1 2026.
  • TD Capital Management sold 44 AbbVie shares in Q1 2026, an estimated $9.76K.
  • AbbVie made up 0.02% of TD Capital Management's portfolio in Q1 2026, its #147 holding.
  • TD Capital Management first reported a position in AbbVie in Q3 2017 and has held it in 23 quarters since.
  • TD Capital Management's AbbVie position peaked at $188K in Q4 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on TD Capital Management's 13F filing for Q1 2026, filed 11 May 2026.